The top global medtech industry dynamics identified by the G-MedTech Research team over the past week, briefly presented in multiple languages.

The Radiological Society of North America (RSNA) and GE HealthCare have announced a collaboration to provide mammography technology, training and educational tools to radiologists at Muhimbili National Hospital (MNH), part of Muhimbili University of Health and Sciences (MUHAS) in Tanzania, where breast cancer is the second leading cause of cancer death, to increase access to screening and help clinicians reduce breast cancer mortality in the country.

3D Systems has received the US FDA 510(k) clearance of its VSP® PEEK Cranial Implant, a 3D-printed, patient-specific cranial implant solution that includes a complete FDA-cleared workflow comprising segmentation and 3D modeling software, the 3D Systems EXT 220 MED 3D printer, Evonik VESTAKEEP® i4 3DF PEEK, and a pre-defined production process.

GE HealthCare has launched two ultrasound systems, Voluson Signature 20 and Voluson Signature 18, that comprehensively integrate artificial intelligence (AI), advanced tools and an ergonomic design to speed exam time for clinicians while delivering a clearer picture of various conditions.

Medtronic has announced the launch of Touch Surgery™ Live Stream for remote observation and enhanced surgical training, and 14 new AI algorithms for post-operative analysis in laparoscopic and robotic-assisted surgery, available through its Touch Surgery™ ecosystem of digital technologies, which also includes surgical video, simulations and case management solutions.

Beijing, China-based TargetingOne has raised RMB100 million ($14 million) in a new round of financing from Beijing Pharmaceutical and Health Industry Investment Fund for the development and commercialisation of its core products, digital PCR systems and point-of-care testing products.

Hangzhou, China-based Seeneuro Medical has closed hundreds of millions of yuan series B financing led by OrbiMed Capital and followed by the existing investor BioTrack Capital, for the research and development, clinical trials, and commercialization of its implantable neurostimulators and brain-computer interface medical devices.

en_GBEnglish (UK)